CliffBio
small molecule

BEVYXXA

BETRIXABAN

Loss of exclusivityMarch 2031latest FDA-listed patent expiry
CompanyPortola Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameBEVYXXA
Active ingredientBETRIXABAN
Strength40MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
8404724March 2031product
8987463December 2030product
8557852September 2028use U-2030
7598276November 2026substance
9555023November 2026use U-1502

More from Portola Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BEVYXXA patent cliff — loss of exclusivity March 2031 | CliffBio